Theravance Biopharma (TBPH) Research & Development (2016 - 2025)
Historic Research & Development for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $8.1 million.
- Theravance Biopharma's Research & Development fell 1247.3% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 822.95%. This contributed to the annual value of $37.6 million for FY2024, which is 733.12% down from last year.
- As of Q3 2025, Theravance Biopharma's Research & Development stood at $8.1 million, which was down 1247.3% from $10.5 million recorded in Q2 2025.
- Theravance Biopharma's Research & Development's 5-year high stood at $67.6 million during Q1 2021, with a 5-year trough of $8.1 million in Q3 2025.
- For the 5-year period, Theravance Biopharma's Research & Development averaged around $19.2 million, with its median value being $10.5 million (2025).
- Its Research & Development has fluctuated over the past 5 years, first crashed by 7744.12% in 2022, then skyrocketed by 2769.85% in 2025.
- Theravance Biopharma's Research & Development (Quarter) stood at $31.2 million in 2021, then plummeted by 50.85% to $15.3 million in 2022, then crashed by 45.84% to $8.3 million in 2023, then grew by 13.71% to $9.5 million in 2024, then fell by 14.19% to $8.1 million in 2025.
- Its Research & Development was $8.1 million in Q3 2025, compared to $10.5 million in Q2 2025 and $11.5 million in Q1 2025.